Aurora Cannabis (NASDAQ:ACB) Stock Crosses Above 50-Day Moving Average – What’s Next?

Posted by George Bondi on Oct 29th, 2026

Shares of Aurora Cannabis Inc. (NASDAQ:ACB – Get Free Report) passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.03 and traded as high as $4.16. Aurora Cannabis shares last traded at $4.15, with a volume of 578,295 shares traded.

Wall Street Analysts Forecast Growth

ACB has been the subject of several recent research reports. Wall Street Zen raised Aurora Cannabis from a “sell” rating to a “hold” rating in a report on Sunday, September 13th. Zacks Research downgraded shares of Aurora Cannabis from a “strong-buy” rating to a “hold” rating in a report on Monday, October 5th. Weiss Ratings upgraded shares of Aurora Cannabis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. Finally, BMO Capital Markets upgraded shares of Aurora Cannabis to a “hold” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Aurora Cannabis presently has a consensus rating of “Hold”.

Get Our Latest Analysis on Aurora Cannabis

Aurora Cannabis Stock Performance

The firm has a 50 day simple moving average of $4.04 and a 200 day simple moving average of $3.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.80 and a current ratio of 5.36. The firm has a market cap of $268.14 million, a P/E ratio of -2.89 and a beta of 0.63.

Aurora Cannabis (NASDAQ:ACB – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.17. Aurora Cannabis had a positive return on equity of 4.37% and a negative net margin of 32.26%. The business had revenue of $47.62 million during the quarter, compared to analyst estimates of $47.45 million. On average, equities research analysts predict that Aurora Cannabis Inc. will post -0.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Aurora Cannabis

Hedge funds have recently bought and sold shares of the company. State of Wyoming boosted its holdings in Aurora Cannabis by 26.2% in the 3rd quarter. State of Wyoming now owns 25,303 shares of the company’s stock valued at $99,000 after purchasing an additional 5,250 shares during the period. Tidal Investments LLC increased its holdings in shares of Aurora Cannabis by 1.2% in the second quarter. Tidal Investments LLC now owns 1,264,494 shares of the company’s stock worth $3,528,000 after purchasing an additional 14,827 shares during the period. Two Sigma Securities LLC bought a new position in shares of Aurora Cannabis in the second quarter worth $36,000. Baader Bank Aktiengesellschaft increased its holdings in shares of Aurora Cannabis by 37.3% in the first quarter. Baader Bank Aktiengesellschaft now owns 33,060 shares of the company’s stock worth $108,000 after purchasing an additional 8,990 shares during the period. Finally, Leonteq Securities AG raised its position in shares of Aurora Cannabis by 24.7% in the first quarter. Leonteq Securities AG now owns 42,839 shares of the company’s stock worth $140,000 after buying an additional 8,472 shares in the last quarter. Hedge funds and other institutional investors own 47.63% of the company’s stock.

Aurora Cannabis Company Profile

(Get Free Report)

Aurora Cannabis Inc is a Canadian cannabis company headquartered in Edmonton, Alberta. Founded in 2013, the company develops, produces, distributes and sells cannabis and cannabis-derived products for medical and adult-use markets. Its shares trade on the Toronto Stock Exchange and the Nasdaq under the symbol ACB.

Aurora’s product portfolio includes dried cannabis flower, pre-rolls, cannabis oils, softgels, vapes and other cannabis extracts. The company markets products through brands such as Aurora, San Rafael ’71, Daily Special and CanniMed, with offerings varying by market and applicable regulations.

The company serves Canada’s regulated adult-use and medical cannabis markets and has expanded its medical cannabis business internationally.